Vitamin K2 supplier Kappa Bioscience forms scientific and medical advisory board

Vitamin K2 ingredient supplier Kappa Bioscience has formed a scientific and medical advisory board “to support and expand the scientific knowledge base for vitamin K2,” including the firm’s branded ingredient K2Vital.

Vitamin K2 ingredient supplier Kappa Bioscience (Oslo, Norway) has formed a scientific and medical advisory board “to support and expand the scientific knowledge base for vitamin K2,” such as the firm’s branded ingredient K2Vital.

“The board reflects Kappa's unique commitment to growing awareness of the rapidly expanding range of benefits associated with vitamin K2 in the form of menaquinone 7 (MK-7),” it said in a press release. “It will include world authorities in relevant fields of science, including cardiology, immunology, kinesiology, and molecular nutrition, and will set a new standard for the scientific support and advancement of emerging nutritional compounds.”

The board has already added the following researchers:

  • John Ivy, PhD, a Teresa Lozano Long Endowed Chair Emeritus at the University of Texas at Austin. Ivy’s research focuses on the effects of exercise and nutritional supplementation of physical performance and wellness.
  • Susanne Talcott, PhD, associate professor at Texas A&M University, Food Science & Technology, Molecular Researcher. Talcott’s focus is translational pharmacokinetics and pharmacodynamics of food compounds and their physiological metabolites related to inflammation, cancer prevention, and intestinal health.
  • Nathan Wong, PhD, MPH, cardiovascular epidemiologist, a specialist in preventive cardiology, and professor and director of the Heart Disease Prevention Program, Division of Cardiology, at the University of California. His research focuses on the epidemiology of diabetes and cardiovascular disease, subclinical atherosclerosis, and dyslipidemia.

More members will be announced soon. The group will be led by Trygve Bergeland, PhD, Kappa’s vice president of science.

“The formation of Kappa's Scientific and Medical Advisory Board is a further demonstration of the company's commitment to maintaining its leadership position in the K2 sector and to bringing its remarkable health benefits to a growing number of consumers worldwide,” stated Egil Greve, Kappa's CEO, in a press release. “We are honored to have attracted this esteemed group of scientists. The top-class experts together have authored over 700 scientific papers. We are confident that with their help, awareness of vitamin K2 and its scope of benefits will rapidly accelerate.”